Literature DB >> 28035686

Interaction Between Atypical Antipsychotics and the Gut Microbiome in a Bipolar Disease Cohort.

Stephanie A Flowers1, Simon J Evans2, Kristen M Ward1, Melvin G McInnis2, Vicki L Ellingrod1,2.   

Abstract

OBJECTIVES: The atypical antipsychotic (AAP) class is often associated with metabolic disease, but the mechanistic underpinnings of this risk are not understood. Due to reports linking gut bacteria function to metabolic disease, we hypothesize that AAP treatment in adults results in gut dysbiosis potentiating metabolic criteria. This report describes recent findings linking AAP treatment with differences in gut microbiota communities in a human cohort with bipolar disorder (BD).
METHODS: In a cross-sectional design, we obtained 16S ribosomal sequences from 117 BD patients (49 AAP treated, 68 non-AAP treated). Analysis of molecular variance (AMOVA) was used to detect significant clustering of microbial communities between groups, and the inverse Simpson Diversity Index was used to calculate alpha diversity. Detection of differentially abundant operational taxonomic units (OTUs) between groups was performed using linear discriminant analysis effect size.
RESULTS: The AAP-treated cohort was significantly younger and had an increased body mass index compared with non-AAP-treated patients. Groups did not differ in other psychotropic medication use with the exception of higher use of benzodiazepines in the AAP cohort. We detected significant separation between microbiota communities of AAP-treated and nontreated patients (AMOVA; p=0.04). AAP-treated females showed significant decreased species diversity when compared with non-AAP-treated females (p=0.015). Males showed no significant diversity between treatment groups (p=0.8). Differentially abundant OTUs between treatment groups were OTU1, OTU25, and OTU32 that classified to Lachnospiraceae, Akkermansia, and Sutterella, respectively.
CONCLUSIONS: These data suggest that AAP treatment is associated with specific representation of gut bacterial families in AAP-treated patients. In addition, AAP treatment is associated with decreased species richness in female AAP-treated patients.
© 2017 Pharmacotherapy Publications, Inc.

Entities:  

Keywords:  atypical antipsychotics; metabolic disease; microbiome

Mesh:

Substances:

Year:  2017        PMID: 28035686     DOI: 10.1002/phar.1890

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  55 in total

1.  Effects of Atypical Antipsychotic Treatment and Resistant Starch Supplementation on Gut Microbiome Composition in a Cohort of Patients with Bipolar Disorder or Schizophrenia.

Authors:  Stephanie A Flowers; Nielson T Baxter; Kristen M Ward; A Zarina Kraal; Melvin G McInnis; Thomas M Schmidt; Vicki L Ellingrod
Journal:  Pharmacotherapy       Date:  2019-02-03       Impact factor: 4.705

2.  Overview and systematic review of studies of microbiome in schizophrenia and bipolar disorder.

Authors:  Tanya T Nguyen; Tomasz Kosciolek; Lisa T Eyler; Rob Knight; Dilip V Jeste
Journal:  J Psychiatr Res       Date:  2018-01-31       Impact factor: 4.791

Review 3.  Drug-induced obesity and its metabolic consequences: a review with a focus on mechanisms and possible therapeutic options.

Authors:  A A Verhaegen; L F Van Gaal
Journal:  J Endocrinol Invest       Date:  2017-06-28       Impact factor: 4.256

4.  When pharmacology meets the microbiome: new targets for therapeutics?

Authors:  Niall P Hyland; John F Cryan
Journal:  Br J Pharmacol       Date:  2018-12       Impact factor: 8.739

5.  Differences in gut microbiome composition between persons with chronic schizophrenia and healthy comparison subjects.

Authors:  Tanya T Nguyen; Tomasz Kosciolek; Yadira Maldonado; Rebecca E Daly; Averria Sirkin Martin; Daniel McDonald; Rob Knight; Dilip V Jeste
Journal:  Schizophr Res       Date:  2018-09-26       Impact factor: 4.939

6.  Interactions of commensal and pathogenic microorganisms with the mucus layer in the colon.

Authors:  Rui Cai; Chen Cheng; Jianwei Chen; Xiaoqiang Xu; Chao Ding; Bing Gu
Journal:  Gut Microbes       Date:  2020-03-29

Review 7.  Microbiota-based approaches to mitigate infectious complications of intensive chemotherapy in patients with acute leukemia.

Authors:  Armin Rashidi; Daniel J Weisdorf
Journal:  Transl Res       Date:  2020-04-05       Impact factor: 7.012

8.  Impact of prior antibiotic use on the efficacy of nivolumab for non-small cell lung cancer.

Authors:  Taiki Hakozaki; Yusuke Okuma; Miwako Omori; Yukio Hosomi
Journal:  Oncol Lett       Date:  2019-01-08       Impact factor: 2.967

Review 9.  Sex Differences in the Gut-Brain Axis: Implications for Mental Health.

Authors:  Calliope Holingue; Alexa Curhan Budavari; Katrina M Rodriguez; Corina R Zisman; Grace Windheim; M Daniele Fallin
Journal:  Curr Psychiatry Rep       Date:  2020-11-20       Impact factor: 5.285

Review 10.  The Gut Microbiome and Treatment-Resistance in Schizophrenia.

Authors:  Mary V Seeman
Journal:  Psychiatr Q       Date:  2020-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.